Hymecromone ( DrugBank: Hymecromone )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 94 | 原発性硬化性胆管炎 | 1 |
94. 原発性硬化性胆管炎
臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05295680 (ClinicalTrials.gov) | November 2022 | 4/3/2022 | Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. | A Study of Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis(HAAPS Study). | Primary Sclerosing Cholangitis | Drug: Hymecromone | Paul Bollyky | NULL | Not yet recruiting | 14 Years | 75 Years | All | 24 | Phase 2 | United States |